SI1506203T1 - Sinteza epotilonov, intermediati za to, analogi in njihove uporabe - Google Patents

Sinteza epotilonov, intermediati za to, analogi in njihove uporabe

Info

Publication number
SI1506203T1
SI1506203T1 SI200330738T SI200330738T SI1506203T1 SI 1506203 T1 SI1506203 T1 SI 1506203T1 SI 200330738 T SI200330738 T SI 200330738T SI 200330738 T SI200330738 T SI 200330738T SI 1506203 T1 SI1506203 T1 SI 1506203T1
Authority
SI
Slovenia
Prior art keywords
epothilones
analogues
intermediates
synthesis
Prior art date
Application number
SI200330738T
Other languages
English (en)
Inventor
Samuel J Danishefsky
Alexey Rivkin
Fumihiko Yoshimura
Ortega Ana Esther Gabarda
Young Shin Cho
Ting-Chao Chou
Huajin Dong
Original Assignee
Sloan Kettering Inst Cancer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37718407&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI1506203(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US10/402,004 external-priority patent/US6921769B2/en
Application filed by Sloan Kettering Inst Cancer filed Critical Sloan Kettering Inst Cancer
Priority claimed from EP03793304A external-priority patent/EP1506203B1/en
Publication of SI1506203T1 publication Critical patent/SI1506203T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
SI200330738T 2002-08-23 2003-08-22 Sinteza epotilonov, intermediati za to, analogi in njihove uporabe SI1506203T1 (sl)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US40582302P 2002-08-23 2002-08-23
US40858902P 2002-09-06 2002-09-06
US42312902P 2002-11-01 2002-11-01
US45615903P 2003-03-20 2003-03-20
US10/402,004 US6921769B2 (en) 2002-08-23 2003-03-28 Synthesis of epothilones, intermediates thereto and analogues thereof
US10/435,408 US7649006B2 (en) 2002-08-23 2003-05-09 Synthesis of epothilones, intermediates thereto and analogues thereof
US49674103P 2003-08-21 2003-08-21
EP03793304A EP1506203B1 (en) 2002-08-23 2003-08-22 Synthesis of epothilones, intermediates thereto, analogues and uses thereof
PCT/US2003/026367 WO2004018478A2 (en) 2002-08-23 2003-08-22 Synthesis of epothilones, intermediates thereto, analogues and uses thereof

Publications (1)

Publication Number Publication Date
SI1506203T1 true SI1506203T1 (sl) 2007-06-30

Family

ID=37718407

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200330738T SI1506203T1 (sl) 2002-08-23 2003-08-22 Sinteza epotilonov, intermediati za to, analogi in njihove uporabe

Country Status (2)

Country Link
US (6) US7649006B2 (sl)
SI (1) SI1506203T1 (sl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69734362T2 (de) * 1996-12-03 2006-07-20 Sloan-Kettering Institute For Cancer Research Synthese von epothilonen, zwischenprodukte dazu, analoga und verwendungen davon
US6596875B2 (en) * 2000-02-07 2003-07-22 James David White Method for synthesizing epothilones and epothilone analogs
US20020058286A1 (en) * 1999-02-24 2002-05-16 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto and analogues thereof
US7649006B2 (en) * 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
DE60330407D1 (de) * 2002-08-23 2010-01-14 Sloan Kettering Inst Cancer Synthese von Epothilonen, Zwischenprodukte davon, Analoga und ihre Verwendung
US7384964B2 (en) * 2002-08-23 2008-06-10 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
SI1562941T1 (sl) * 2002-11-07 2010-05-31 Kosan Biosciences Inc Trans dehidroepotilon c in d njihovi analogi in postopek za izdelavo le teh
US20050256097A1 (en) * 2004-05-11 2005-11-17 Kosan Biosciences, Inc. Pharmaceutical solution formulations containing 17-AAG
US7238816B2 (en) * 2005-04-21 2007-07-03 Hoffmann-La Roche Inc. Preparation of epothilone derivatives

Family Cites Families (232)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4605661A (en) * 1984-06-18 1986-08-12 Eli Lilly And Company Aromastase inhibiting α,α-diarylimidazole-4(5)-propionitriles, α,α-diarylimidazole-4(5)-propionamides, and 4(5)-(2,2-diarylethyl)imidazoles
EP0225292A3 (en) 1985-12-06 1988-11-30 Ciba-Geigy Ag Certain n-substituted butyramide derivatives
DE3811574A1 (de) * 1988-03-31 1989-10-19 Schering Ag N-substituierte imidazole, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln
DE4138042C2 (de) 1991-11-19 1993-10-14 Biotechnolog Forschung Gmbh Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel
US20030203976A1 (en) 1993-07-19 2003-10-30 William L. Hunter Anti-angiogenic compositions and methods of use
DK0797988T3 (da) 1993-07-19 2009-05-11 Univ British Columbia Anti-angiogene præparater og fremgangsmåder til anvendelse deraf
US5716981A (en) 1993-07-19 1998-02-10 Angiogenesis Technologies, Inc. Anti-angiogenic compositions and methods of use
WO1995003035A1 (en) 1993-07-23 1995-02-02 Massachusetts Institute Of Technology Polymerized liposomes with enhanced stability for oral delivery
EP0873341B1 (de) 1995-11-17 2003-09-10 Gesellschaft für biotechnologische Forschung mbH (GBF) Epothilonderivate, herstellung und verwendung
DE19607702A1 (de) 1996-02-29 1997-09-04 Biotechnolog Forschung Gmbh Heterozyklische Verbindungen, Herstellungsverfahren und Mittel
US6441025B2 (en) 1996-03-12 2002-08-27 Pg-Txl Company, L.P. Water soluble paclitaxel derivatives
PT932399E (pt) 1996-03-12 2006-05-31 Pg Txl Co Lp Pro-farmacos de paclitaxel hidrossoluveis
US20040106985A1 (en) 1996-04-26 2004-06-03 Jang G. David Intravascular stent
US5917084A (en) 1996-07-03 1999-06-29 Millennium Pharmaceuticals, Inc. Antifungal agents
US5969145A (en) 1996-08-30 1999-10-19 Novartis Ag Process for the production of epothilones and intermediate products within the process
DE19645362A1 (de) 1996-10-28 1998-04-30 Ciba Geigy Ag Verfahren zur Herstellung von Epothilon A und B und Derivaten
DE19636343C1 (de) 1996-08-30 1997-10-23 Schering Ag Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B
DE19645361A1 (de) 1996-08-30 1998-04-30 Ciba Geigy Ag Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B, Teil II
DE19638870B4 (de) 1996-09-23 2009-05-14 Helmholtz-Zentrum für Infektionsforschung GmbH Tubulysine, Verfahren zu ihrer Gewinnung und sie enthaltende Mittel
DE69734362T2 (de) 1996-12-03 2006-07-20 Sloan-Kettering Institute For Cancer Research Synthese von epothilonen, zwischenprodukte dazu, analoga und verwendungen davon
US6204388B1 (en) 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6867305B2 (en) 1996-12-03 2005-03-15 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6660758B1 (en) 1996-12-13 2003-12-09 The Scripps Research Institute Epothilone analogs
US6380394B1 (en) 1996-12-13 2002-04-30 The Scripps Research Institute Epothilone analogs
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
DE19701758A1 (de) 1997-01-20 1998-07-23 Wessjohann Ludgar A Dr Epothilone-Synthesebausteine
DE19880193D2 (de) 1997-02-25 2000-08-24 Biotechnolog Forschung Gmbh Seitenkettenmodifizierte Epothilone
US20020086812A1 (en) 1997-03-04 2002-07-04 Schweinfest Clifford W. Methods and compositions for diagnosis and treatment of cancer
DE19713970B4 (de) 1997-04-04 2006-08-31 R&D-Biopharmaceuticals Gmbh Epothilone-Synthesebausteine II - Prenylderivate
JP4065573B2 (ja) 1997-04-18 2008-03-26 ベーリンガー・インゲルハイム・インテルナツィオナール・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 反応媒体として圧縮二酸化炭素中における二官能性または多官能性基質の選択的オレフィンメタセシス
US6117659A (en) 1997-04-30 2000-09-12 Kosan Biosciences, Inc. Recombinant narbonolide polyketide synthase
DE19849464A1 (de) 1997-04-30 2000-04-27 Schering Ag Wirkstofffreisetzende Stents, Verfahren zu ihrer Herstellung und ihre Verwendung zur Restenoseprophylaxe
DE19821954A1 (de) 1997-05-15 1998-11-19 Biotechnolog Forschung Gmbh Verfahren zur Herstellung eines Epothilon-Derivats
DE19720312A1 (de) 1997-05-15 1998-11-19 Hoechst Ag Zubereitung mit erhöhter in vivo Verträglichkeit
GB9801231D0 (en) 1997-06-05 1998-03-18 Merck & Co Inc A method of treating cancer
US20030049841A1 (en) 1997-06-16 2003-03-13 Short Jay M. High throughput or capillary-based screening for a bioactivity or biomolecule
DE19726627A1 (de) 1997-06-17 1998-12-24 Schering Ag Zwischenprodukte, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von Epothilon
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
ATE224882T1 (de) 1997-07-16 2002-10-15 Schering Ag Thiazolderivate, verfahren zur herstellung und verwendung
DE19735578A1 (de) 1997-08-09 1999-02-11 Schering Ag Neue (C1-C6)-Fragmente, Verfahren zur Herstellung und ihre Verwendung zur Synthese von Epothilon und Epothilonderivaten
DE19751200A1 (de) 1997-11-13 1999-05-20 Schering Ag Neue Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung
DE19735575A1 (de) 1997-08-09 1999-02-11 Schering Ag Neue (C13-C15)-Fragmente, Verfahren zur Herstellung und ihre Verwendung zur Synthese von Epothilon und Epothilonderivaten
DE19749717A1 (de) 1997-10-31 1999-05-06 Schering Ag Neue C1-C6-Bausteine zur Totalsynthese neuer Epothilon-Derivate sowie Verfahren zur Herstellung dieser Bausteine
DE19735574A1 (de) 1997-08-09 1999-02-11 Schering Ag Neue [C1(Carboxa)-C6]-Fragmente, Verfahren zu ihrer Herstellung und ihre Verwendung zur Synthese von Epothilon und Epothilonderivaten
DE19813821A1 (de) 1998-03-20 1999-09-23 Schering Ag Verfahren zur Herstellung von C1-C6-Bausteinen zur Totalsynthese von Epothilon und Epothilon-Derivaten
CA2299608A1 (en) 1997-08-09 1999-02-18 Schering Aktiengesellschaft New epothilone derivatives, method for producing same and their pharmaceutical use
DE19744135C1 (de) 1997-09-29 1999-03-25 Schering Ag Beschichtete medizinische Implantate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Restenoseprophylaxe
HUP0100582A3 (en) 1997-12-04 2003-03-28 Bristol Myers Squibb Co A process for the reduction of oxiranyl epothilones to olefinic epothilones
US6365749B1 (en) 1997-12-04 2002-04-02 Bristol-Myers Squibb Company Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
US6320045B1 (en) 1997-12-04 2001-11-20 Bristol-Myers Squibb Company Process for the reduction of oxiranyl epothilones to olefinic epothilones
US6096757A (en) 1998-12-21 2000-08-01 Schering Corporation Method for treating proliferative diseases
US6090601A (en) 1998-01-23 2000-07-18 Kosan Bioscience Sorangium polyketide synthase
US6280999B1 (en) 1998-01-23 2001-08-28 Kosan Bioscience Sorangium polyketide synthases and encoding DNA therefor
CA2320182C (en) 1998-02-05 2008-11-25 Novartis Ag Compositions containing organic compounds
US6683100B2 (en) 1999-01-19 2004-01-27 Novartis Ag Organic compounds
DE19804673A1 (de) 1998-02-06 1999-08-12 Studiengesellschaft Kohle Mbh Verfahren zur Darstellung makrocyclischer Produkte durch ringschliessende Diin-Metathese
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
US6302838B1 (en) 1998-02-25 2001-10-16 Novartis Ag Cancer treatment with epothilones
NZ506742A (en) 1998-02-25 2003-09-26 Sloan Kettering Inst Cancer Synthesis of desoxyepothilones and hydroxy acid derivative intermediates
FR2775187B1 (fr) 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
US6380395B1 (en) 1998-04-21 2002-04-30 Bristol-Myers Squibb Company 12, 13-cyclopropane epothilone derivatives
US6498257B1 (en) 1998-04-21 2002-12-24 Bristol-Myers Squibb Company 2,3-olefinic epothilone derivatives
US6407103B2 (en) 1998-04-21 2002-06-18 Bristol-Myers Squibb Pharma Company Indeno [1,2-c] pyrazol-4-ones and their uses
GB9810659D0 (en) 1998-05-18 1998-07-15 Ciba Geigy Ag Organic compounds
US6121029A (en) 1998-06-18 2000-09-19 Novartis Ag Genes for the biosynthesis of epothilones
DE19826988A1 (de) 1998-06-18 1999-12-23 Biotechnolog Forschung Gmbh Epothilon-Nebenkomponenten
DE19830060A1 (de) 1998-06-30 2000-02-10 Schering Ag Epothilon-Derivate, Verfahren zu deren Herstellung, Zwischenprodukte und ihre pharmazeutische Verwendung
DE19923001A1 (de) 1999-05-13 2000-11-16 Schering Ag Epothilon-Derivate, Verfahren zu deren Herstellung, Zwischenprodukte und ihre pharmazeutische Verwendung
JP2002525026A (ja) 1998-07-02 2002-08-13 ザ ボード オブ リージェンツ オブ ザ レランド スタンフォード ジュニア ユニバーシティ ポリケチドを作製するための方法
US20030199535A1 (en) 1998-07-30 2003-10-23 Claudio Cavazza Method for preventing and/or treating peripheral neuropathies induced by the administration of an anticancer agent
CN1329668A (zh) 1998-10-02 2002-01-02 高山生物科学股份有限公司 多聚乙酰合成酶及其重组dna构建物
DE19846493A1 (de) 1998-10-09 2000-04-13 Biotechnolog Forschung Gmbh DNA-Sequenzen für die enzymatische Synthese von Polyketid- oder Heteropolyketidverbindungen
DE19848306A1 (de) 1998-10-14 2000-04-20 Schering Ag Verfahren zur Herstellung von Epothilon B und Derivaten sowie Zwischenprodukte für dieses Verfahren
JP2003512013A (ja) 1998-10-29 2003-04-02 コーサン バイオサイエンシーズ， インコーポレイテッド 組換えオレアンドライドポリケチドシンターゼ
US6303767B1 (en) 1998-11-05 2001-10-16 Kosan Biosciences, Inc. Nucleic acids encoding narbonolide polyketide synthase enzymes from streptomyces narbonensis
US6303342B1 (en) 1998-11-20 2001-10-16 Kason Biosciences, Inc. Recombinant methods and materials for producing epothilones C and D
US6410301B1 (en) 1998-11-20 2002-06-25 Kosan Biosciences, Inc. Myxococcus host cells for the production of epothilones
CA2352505C (en) 1998-12-22 2009-04-07 Novartis Ag Epothilone derivatives and their use as antitumor agents
US6780620B1 (en) 1998-12-23 2004-08-24 Bristol-Myers Squibb Company Microbial transformation method for the preparation of an epothilone
US6419692B1 (en) 1999-02-03 2002-07-16 Scimed Life Systems, Inc. Surface protection method for stents and balloon catheters for drug delivery
US6596875B2 (en) 2000-02-07 2003-07-22 James David White Method for synthesizing epothilones and epothilone analogs
DE19908765A1 (de) 1999-02-18 2000-08-24 Schering Ag 16-Halogen-Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung
DE19908767A1 (de) 1999-02-18 2000-10-19 Schering Ag Neue Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung
DE19908760A1 (de) 1999-02-18 2000-08-24 Schering Ag Neue Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung
DE19954230A1 (de) 1999-11-04 2001-11-15 Schering Ag 16-Halogen-Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung
AU776511B2 (en) 1999-02-18 2004-09-09 Baylor University Compositions and methods for use in targeting vascular destruction
US6406722B1 (en) 1999-02-18 2002-06-18 Robert G. Gallaher Method of treating viral infections and lesions with taxane compounds
DE19908763A1 (de) 1999-02-18 2000-08-24 Schering Ag Neue Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung
IL144519A0 (en) 1999-02-18 2002-05-23 Schering Ag 16-halogen-epothilone derivatives, method for producing them and their pharmaceutical use
DE19930111A1 (de) 1999-07-01 2001-01-04 Biotechnolog Forschung Gmbh C-21 Modifizierte Epothilone
US6262094B1 (en) 1999-02-22 2001-07-17 Bristol-Myers Squibb Company C-21 modified epothilones
DE19907588A1 (de) 1999-02-22 2000-08-24 Biotechnolog Forschung Gmbh C-21 Modifizierte Epothilone
US20020058286A1 (en) 1999-02-24 2002-05-16 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto and analogues thereof
GB2347998A (en) 1999-03-16 2000-09-20 Litron Optical Limited Method and apparatus for measuring the intensity of a beam of light
US6211412B1 (en) 1999-03-29 2001-04-03 The University Of Kansas Synthesis of epothilones
US6603015B2 (en) 1999-03-29 2003-08-05 University Of Kansas Synthesis of epothilones
US6291684B1 (en) 1999-03-29 2001-09-18 Bristol-Myers Squibb Company Process for the preparation of aziridinyl epothilones from oxiranyl epothilones
DE60013347T2 (de) 1999-04-06 2005-09-08 Seiko Epson Corp. Tintenzusammensetzung enthaltend einen Kupferkomplex-Farbstoff
ES2273688T3 (es) 1999-04-14 2007-05-16 Dana-Farber Cancer Institute, Inc. Procedimiento y composicion para el tratamiento de cancer.
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
EP2308833A3 (en) 1999-04-15 2011-09-28 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
DE10015836A1 (de) 2000-03-27 2001-10-11 Schering Ag 6-Alkenyl- und 6-Alkinyl-Epothilon-Derivate, Verfahren zu deren Herstellung sowie ihre Verwendung in pharmazeutischen Präparaten
DE19954228A1 (de) 1999-11-04 2001-09-13 Schering Ag 6-Alkenyl-und 6-Alkinyl-Epothilon-Derivate, Verfahren zu deren Herstellung sowie ihre Verwendung in pharmazeutischen Präparaten
KR100621185B1 (ko) * 1999-09-09 2006-09-06 삼성전자주식회사 디디씨 모니터의 동작 기록형 마이크로컴퓨터의 제어방법
US6569867B2 (en) 1999-10-01 2003-05-27 Kosan Biosciences, Inc. Polyketide derivatives
US20020147197A1 (en) 1999-10-08 2002-10-10 Newman Michael J. Methods and compositions for enhancing pharmaceutical treatments
US20030054977A1 (en) 1999-10-12 2003-03-20 Cell Therapeutics, Inc. Manufacture of polyglutamate-therapeutic agent conjugates
US20020045220A1 (en) 1999-10-13 2002-04-18 Chaitan Khosla Biosynthesis of polyketide synthase substrates
JP2001116917A (ja) 1999-10-18 2001-04-27 Hitachi Ltd 画像品位向上部材及びこれを用いた画像表示装置
US20030036177A1 (en) 2002-08-13 2003-02-20 Joachim Strohhacker Single colonies of myxobacteria cells
US6518421B1 (en) 2000-03-20 2003-02-11 Bristol-Myers Squibb Company Process for the preparation of epothilone analogs
US6593115B2 (en) 2000-03-24 2003-07-15 Bristol-Myers Squibb Co. Preparation of epothilone intermediates
TWI310684B (en) 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
DE10020517A1 (de) 2000-04-19 2001-10-25 Schering Ag Neue Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung
DE10020899A1 (de) 2000-04-20 2001-10-25 Schering Ag 9-Oxa-Epothilon-Derivate, Verfahren zu deren Herstellung sowie ihre Verwendung in pharmazeutischen Präparaten
US6589968B2 (en) 2001-02-13 2003-07-08 Kosan Biosciences, Inc. Epothilone compounds and methods for making and using the same
US6998256B2 (en) 2000-04-28 2006-02-14 Kosan Biosciences, Inc. Methods of obtaining epothilone D using crystallization and /or by the culture of cells in the presence of methyl oleate
US6489314B1 (en) 2001-04-03 2002-12-03 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same
EP1278882A4 (en) 2000-05-02 2004-08-18 Kosan Biosciences Inc OVER PRODUCTION INNOVERS FOR THE BIOSYNTHESIS OF POLYKETIDES
US20020045609A1 (en) 2000-05-26 2002-04-18 Gary Ashley Epothilone derivatives and methods for making and using the same
US20020137152A1 (en) 2000-07-25 2002-09-26 Daniel Santi Fermentation process for epothilones
AU2001283275A1 (en) 2000-08-09 2002-02-18 Kosan Biosciences, Inc. Bio-intermediates for use in the chemical synthesis of polyketides
UA75365C2 (en) 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
PL366061A1 (en) 2000-08-30 2005-01-24 Kimberly-Clark Worldwide, Inc. Tear-resistant adhesive/combination bond pattern
US7766956B2 (en) 2000-09-22 2010-08-03 Boston Scientific Scimed, Inc. Intravascular stent and assembly
IL155306A0 (en) 2000-10-13 2003-11-23 Univ Mississippi Methods for producing epothilone derivatives and analogs and epothilone derivatives and analogs produced thereby
EP1358144B1 (de) 2000-10-16 2006-12-27 R&D-Biopharmaceuticals Epothilon-synthesebausteine i: unsymmetrisch substituierte acyloine und acyloinderivate, verfahren zu deren herstellung sowie deren verwendung zur herstellung von epothilonen und epothilonderivaten
DE10051136A1 (de) 2000-10-16 2002-04-18 Ludger A Wessjohann Epothilone-Synthesebausteine III und Verfahren zur Herstellung von Epothilon B, D und Epothilonderivaten
US7070797B2 (en) 2000-11-07 2006-07-04 Dana Farber Cancer Institute, Inc. Method of treating hematologic tumors and cancers
US20020169135A1 (en) 2000-11-07 2002-11-14 Pardee Arthur B. Method of treating hematologic tumors and cancers
US20040038324A1 (en) 2000-11-22 2004-02-26 Atadja Peter Wisdom. Epothilone resistant cell lines
GB0029895D0 (en) 2000-12-07 2001-01-24 Novartis Ag Organic compounds
KR100851719B1 (ko) 2001-01-25 2008-08-11 브리스톨-마이어스스퀴브컴파니 암 치료용 에포틸론 유사체의 투여 방법
EP1353667A1 (en) 2001-01-25 2003-10-22 Bristol-Myers Squibb Company Parenteral formulations containing epothilone analogs
NZ526871A (en) 2001-01-25 2006-01-27 Bristol Myers Squibb Co Pharmaceutical dosage forms of epothilones for oral administration
US20030004338A1 (en) 2001-02-01 2003-01-02 Li Wen Sen Process for the preparation of epothilone analogs
US6893859B2 (en) 2001-02-13 2005-05-17 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same
EP1385529A4 (en) 2001-02-20 2007-05-09 Bristol Myers Squibb Co TREATMENT OF REFRACTORY TUMORS USING EPOTHILONE DERIVATIVES
RU2003128312A (ru) 2001-02-20 2005-02-10 Бристол-Маерс Сквибб Компани (Us) Производные эпотилона, используемые для лечения резистентных опухлей
CN1511036B (zh) 2001-02-27 2010-05-05 诺瓦提斯公司 包含信号转导抑制剂和埃坡霉素衍生物的联合形式
MXPA03007466A (es) 2001-02-27 2003-12-08 Gbf Ges F R Biotechnologische Degradacion de epotilonas y epotilonas substituidas con etileno.
US7312237B2 (en) 2001-03-14 2007-12-25 Bristol-Myers Squibb Co. Combination of epothilone analogs and chemotherapeutic agents for the treatment of prolilferative diseases
IL157333A0 (en) 2001-03-19 2004-02-19 Novartis Ag Combinations comprising an antidiarrheal agent and an epothilone or an epothilone derivative
US20020169125A1 (en) 2001-03-21 2002-11-14 Cell Therapeutics, Inc. Recombinant production of polyanionic polymers and uses thereof
IL157993A0 (en) 2001-03-23 2004-03-28 Napro Biotherapeutics Inc Molecular conjugates for use in cancer treatment and methods for the preparation thereof
US7081454B2 (en) 2001-03-28 2006-07-25 Bristol-Myers Squibb Co. Tyrosine kinase inhibitors
US6900214B2 (en) 2001-03-29 2005-05-31 Bristol-Myers Squibb Company Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
JP3902763B2 (ja) 2001-03-30 2007-04-11 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ データビットストリームをデコード及び変換する方法及び装置並びに信号及びレコードキャリア
EP1389090A2 (en) 2001-04-26 2004-02-18 Board of Regents, The University of Texas System Diagnostic imaging compositions, their methods of synthesis and use
US6906188B2 (en) 2001-04-30 2005-06-14 State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University Method for synthesizing epothilones and epothilone analogs
US20030023082A1 (en) 2001-05-15 2003-01-30 Gary Ashley Epothilone derivatives and methods for making and using the same
JP2004532888A (ja) 2001-06-01 2004-10-28 ブリストル−マイヤーズ　スクイブ　カンパニー エポチロン誘導体
CN1543356B (zh) 2001-06-25 2011-09-28 味之素株式会社 抗肿瘤剂
US6933385B2 (en) 2001-08-03 2005-08-23 Schering Ag Protected 3,5-dihydroxy-2,2-dimethyl-valeroamides for the synthesis of epothilones and derivatives and process for the production and the use
DE10138347A1 (de) 2001-08-03 2003-02-27 Schering Ag Geschützte 3,5-Dihydroxy-2,2-dimethyl-valeronitrile für die Synthese von Epothilonen- und Derivaten und Verfahren zur Herstellung
US6872715B2 (en) 2001-08-06 2005-03-29 Kosan Biosciences, Inc. Benzoquinone ansamycins
WO2003018002A2 (en) 2001-08-23 2003-03-06 Novartis Ag Cyclopropyl and cyclobutyl epothilone analogs
HUP0402341A3 (en) 2001-08-31 2005-11-28 Bristol Myers Squibb Company P Compositions containing thiazol-2-ylamines for the treatment of cancer
PL369108A1 (en) 2001-09-06 2005-04-18 Schering Corporation 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
US20030176368A1 (en) 2001-09-06 2003-09-18 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto and analogues thereof
WO2003029195A1 (fr) 2001-09-28 2003-04-10 Sumika Fine Chemicals Co., Ltd. Intermediaires pour l'elaboration d'un derive de l'epothilone, et leur procede de production
TW200300350A (en) 2001-11-14 2003-06-01 Bristol Myers Squibb Co C-5 modified indazolylpyrrolotriazines
AU2002360430A1 (en) 2001-11-26 2003-06-10 Kosan Biosciences, Inc. 14-methyl-epothilones
WO2003047586A1 (en) 2001-12-03 2003-06-12 Schering Corporation Use of fpt inhibitors and at least two antineoplastic agents in the treatment of cancer
TWI287986B (en) 2001-12-13 2007-10-11 Novartis Ag Use of Epothilones for the treatment of the carcinoid syndrome
DE10164592A1 (de) 2001-12-21 2003-07-03 Schering Ag C1-C6-Epothilon-Fragmente und Verfahren für die Herstellung von C1-C6-Fragmenten von Epothilonen und deren Derivaten
US6884608B2 (en) 2001-12-26 2005-04-26 Bristol-Myers Squibb Company Compositions and methods for hydroxylating epothilones
TW200303202A (en) 2002-02-15 2003-09-01 Bristol Myers Squibb Co Method of preparation of 21-amino epothilone derivatives
EP1340498A1 (en) 2002-03-01 2003-09-03 Schering Aktiengesellschaft Use of epothilones in the treatment of brain diseases associated with proliferative processes
WO2003074521A1 (en) 2002-03-01 2003-09-12 University Of Notre Dame Derivatives of epothilone b and d and synthesis thereof
AU2003216491A1 (en) 2002-03-07 2003-09-22 The Board Of Trustees Of The University Of Illinois Microtubule stabilizing compounds
AU2003218110A1 (en) 2002-03-12 2003-09-29 Bristol-Myers Squibb Company C3-cyano epothilone derivatives
AU2003218107A1 (en) 2002-03-12 2003-09-29 Bristol-Myers Squibb Company C12-cyano epothilone derivatives
US6900208B2 (en) 2002-03-28 2005-05-31 Bristol Myers Squibb Company Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders
TW200400191A (en) 2002-05-15 2004-01-01 Bristol Myers Squibb Co Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
CN101389334A (zh) 2002-05-20 2009-03-18 高山生物科学股份有限公司 埃坡霉素d的给药方法
WO2003105828A1 (en) 2002-06-14 2003-12-24 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
TW200401638A (en) 2002-06-20 2004-02-01 Bristol Myers Squibb Co Heterocyclic inhibitors of kinases
DE10232094A1 (de) 2002-07-15 2004-02-05 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) 5-Thiaepothilone und 15-disubstituierte Epothilone
TWI329112B (en) 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
AU2003253365A1 (en) 2002-07-31 2004-02-23 Schering Ag New effector conjugates, process for their production and their pharmaceutical use
AU2003265349A1 (en) 2002-08-02 2004-02-23 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
WO2004014919A1 (en) 2002-08-02 2004-02-19 Novartis Ag Epothilone derivatives
WO2004016269A1 (en) 2002-08-17 2004-02-26 The Queens Universlty Of Belfast Use of vinca alkaloyds, taxane, cryptophycine, ephitoline or eleutherobine for treating alzheimer
EP1391213A1 (en) 2002-08-21 2004-02-25 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
US20040126379A1 (en) 2002-08-21 2004-07-01 Boehringer Ingelheim International Gmbh Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents
AU2003265608A1 (en) 2002-08-21 2004-03-11 Kosan Biosciences, Inc. Myxococcus xanthus bacteriophage mx9 transformation and integration system
US7384964B2 (en) * 2002-08-23 2008-06-10 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
CA2495913A1 (en) 2002-08-23 2004-03-04 Medigene Oncology Gmbh Non-vesicular cationic lipid formulations
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
DE60330407D1 (de) 2002-08-23 2010-01-14 Sloan Kettering Inst Cancer Synthese von Epothilonen, Zwischenprodukte davon, Analoga und ihre Verwendung
NZ539163A (en) 2002-09-04 2007-03-30 Schering Corp Pyrazolo[1,5-a]pyrimidine compounds useful as cyclin dependent kinase (CDK) inhibitors
KR20050058507A (ko) 2002-09-04 2005-06-16 쉐링 코포레이션 사이클린 의존성 키나제 억제제로서의 피라졸로피리미딘
ES2291665T3 (es) 2002-09-04 2008-03-01 Schering Corporation Pirazolopirimidinas como inhibidores de quinasas dependientes de ciclinas.
US20040043089A1 (en) 2002-09-04 2004-03-04 Rabie A-Bakr M Buguzhi agent and composition and methods of preparing and administering the same
AU2003298571B2 (en) 2002-09-04 2006-10-19 Merck Sharp & Dohme Corp. Pyrazolo[1,5-a]pyrimidines compounds as cyclin dependent kinase inhibitors
GB0221312D0 (en) 2002-09-13 2002-10-23 Novartis Ag Organic compounds
CA2499145A1 (en) 2002-09-16 2004-03-25 Agcert International, Llc Food-borne pathogen and spoilage detection device and method
AU2003295332B2 (en) 2002-09-19 2007-01-18 Merck Sharp & Dohme Corp. Imidazopyridines as cyclin dependent kinase inhibitors
JP4845380B2 (ja) 2002-09-19 2011-12-28 シェーリング コーポレイション サイクリン依存性キナーゼインヒビターとしてのピラゾロピリミジン
DE10244847A1 (de) 2002-09-20 2004-04-01 Ulrich Prof. Dr. Speck Medizinische Vorrichtung zur Arzneimittelabgabe
EP1542693A1 (en) 2002-09-23 2005-06-22 Shering Corporation Novel imidazopyrazines as cyclin dependent kinase inhibitors
MY134589A (en) 2002-09-23 2007-12-31 Schering Corp Imidazopyrazines as cyclin dependent kinase inhibitors
EP2287168B1 (en) 2002-09-23 2013-02-13 Bristol-Myers Squibb Company Methods for the preparation, isolation and purification of epothilone B, and X-ray crystal structures of epothilone B
US20040058899A1 (en) 2002-09-25 2004-03-25 Klimko Peter G. Use of epothilones and analogs in conjunction with ophthalmic surgery
WO2004030620A2 (en) 2002-09-30 2004-04-15 Bristol-Myers Squibb Company Novel tyrosine kinase inhibitors
TW200501960A (en) 2002-10-02 2005-01-16 Bristol Myers Squibb Co Synergistic kits and compositions for treating cancer
CA2499682A1 (en) 2002-10-09 2004-04-22 Kosan Biosciences, Inc. Epo d + 5-fu/gemcitabine
AU2003279911A1 (en) 2002-10-09 2004-05-04 Kosan Biosciences, Inc. Therapeutic formulations
WO2004032923A1 (en) 2002-10-11 2004-04-22 Dana-Farber Cancer Institute Inc Epothilone derivatives for the treatment of multiple myeloma
US20060142354A1 (en) 2002-10-15 2006-06-29 Woltering Eugene A Use of epothilone derivatives for the treatment of hyperparathyroidism
CA2505520C (en) 2002-11-06 2012-07-17 Azaya Therapeutics, Inc. Protein-stabilized liposomal formulations of pharmaceutical agents
SI1562941T1 (sl) 2002-11-07 2010-05-31 Kosan Biosciences Inc Trans dehidroepotilon c in d njihovi analogi in postopek za izdelavo le teh
TW200418508A (en) 2002-11-14 2004-10-01 Newbiotics Inc Peptide deformylase activated prodrugs
US7645782B2 (en) 2002-11-28 2010-01-12 Wolfgang Richter Thia-epothilone derivatives for the treatment of cancer
AU2003291872A1 (en) 2002-12-04 2004-06-23 Inrs (Institut National De Recherche Scientifique) An exopolysaccharides delivery system for active molecules
JP2006510626A (ja) 2002-12-05 2006-03-30 シエーリング アクチエンゲゼルシャフト 増殖疾患の処理における部位特異的供給のためのエポチロン類似体
DE10256982A1 (de) 2002-12-05 2004-06-24 Schering Ag Neue Effektor-Konjugate, Verfahren zu Ihrer Herstellung und Ihre Pharmazeutische Verwendung
KR20190034694A (ko) 2002-12-09 2019-04-02 아브락시스 바이오사이언스, 엘엘씨 약리학적 물질의 조성물 및 그 전달방법
BR0317150A (pt) 2002-12-09 2005-11-01 Novartis Ag Estabilizadores de microtúbulos em stents para o tratamento de estenose
AU2003297832A1 (en) 2002-12-09 2004-06-30 Medtronic Vascular Modular stent having polymer bridges at modular unit contact sites
AU2003303058A1 (en) 2002-12-12 2004-07-09 Conforma Therapeutics Corporation Cytotoxins and diagnostic imaging agents comprising hsp90 ligands
EP1572242B1 (en) 2002-12-13 2014-04-16 Immunomedics, Inc. Immunoconjugates with an intracellularly-cleavable linkage
TW200420565A (en) 2002-12-13 2004-10-16 Bristol Myers Squibb Co C-6 modified indazolylpyrrolotriazines
GB0230024D0 (en) 2002-12-23 2003-01-29 Novartis Ag Organic compounds
US7189716B2 (en) 2003-01-03 2007-03-13 Bristol-Myers Squibb Company Tyrosine kinase inhibitors
AU2003219947A1 (en) 2003-02-26 2004-09-28 Bristol-Myers Squibb Company Compositions and methods for hydroxylating epothilones
GB0305928D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
GB0306907D0 (en) 2003-03-26 2003-04-30 Angiogene Pharm Ltd Boireductively-activated prodrugs
KR20050119665A (ko) 2003-03-28 2005-12-21 코산 바이오사이언시즈, 인코포레이티드 재발협착증을 예방하기 위한 장치, 방법 및 조성물
US7955824B2 (en) * 2007-05-11 2011-06-07 Kosan Biosciences Incorporated Methods of making epothilones

Also Published As

Publication number Publication date
US20140213618A1 (en) 2014-07-31
US7649006B2 (en) 2010-01-19
US20120316348A1 (en) 2012-12-13
US8110590B2 (en) 2012-02-07
US8513429B2 (en) 2013-08-20
US20070032534A1 (en) 2007-02-08
US7759374B2 (en) 2010-07-20
US20150175587A1 (en) 2015-06-25
US20040053910A1 (en) 2004-03-18
US20100197746A1 (en) 2010-08-05

Similar Documents

Publication Publication Date Title
GB0216654D0 (en) CVD Synthesis of carbon nanoutubes
PT1644384E (pt) Processo e intermediários para a síntese de entecavir
AU2003225551A8 (en) Synthesis of 2h- and 13c- substituted dithianes
AU156078S (en) Set of cannula heads
SI1476162T1 (sl) Nadzirana sinteza ziprasidona
IL223579A0 (en) Synthesis of amines and intermediates for the synthesis thereof
EP1722791A4 (en) SYNTHESIS OF EPOTHILONES, INTERMEDIATES THEREOF, ANALOGUES AND ITS USES
AU2003248647A8 (en) Stereoselective synthesis of 1,2-disubstituted cycloalkyls
SI1506203T1 (sl) Sinteza epotilonov, intermediati za to, analogi in njihove uporabe
AU2003295684A8 (en) Synthesis of 3,5-dihydroxy-7-pyrrol-1-yl heptanoic acids
AU2003246963A8 (en) Synthesis of cyclohexanone derivatives
GB0204140D0 (en) Production of olefins
AU2003218176A1 (en) Asymetric synthesis of amino-pyrrolidinones
AU2003263090A1 (en) Analogs of discodermolide and dictyostatin-1, intermediates therefor and methods of synthesis thereof
MXPA02004180A (es) Metodos de sintesis de dl-hidroxi-alquil-fenil amidas.
AU2003225642A1 (en) Mappicine analogs, intermediates in the synthesis of mappicine analogs and methods of synthesis of mappicine analogs
AU2003217354A8 (en) Synthesis of sulfamidates
AU2003238034A1 (en) Novel use of imidazotriazinones
AU2003226717A8 (en) Intermediates for the synthesis of discodermolide and related analogues and methods for their preparation
PL375437A1 (en) Synthesis of gatifloxacin
AU2003251431A1 (en) Synthesis of discodermolide
AU2002329988A1 (en) Synthesis of epothilones intermediates thereto and analogues thereof
GB0225106D0 (en) Synthesis of 3 hydroxy-5 -steroids
AU2003218407A1 (en) Synthesis of 2,6-dicarbonylpyridines
EP1511485A4 (en) NOVEL USES OF I DL / I -TETRAHYDROPALMATIN